Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

350f38a2-e597-494a-a387-975814453726

—

2b57103b-8583-5d13-b4a9-d260820479d0

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • MYC_TARGETS_V2+0.500
  • ANGIOGENESIS+0.400
  • MYC_TARGETS_V1+0.400
  • TGF_BETA_SIGNALING+0.400
  • GLYCOLYSIS+0.300
  • HYPOXIA+0.300
  • PANCREAS_BETA_CELLS+0.300
  • UNFOLDED_PROTEIN_RESPONSE+0.300
  • G2M_CHECKPOINT+0.200

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.500
  • INTERFERON_ALPHA_RESPONSE-0.500
  • INTERFERON_GAMMA_RESPONSE-0.500
  • CHOLESTEROL_HOMEOSTASIS-0.300
  • HEME_METABOLISM-0.300
  • APICAL_SURFACE-0.200
  • APOPTOSIS-0.200
  • BILE_ACID_METABOLISM-0.200
  • COMPLEMENT-0.200
  • FATTY_ACID_METABOLISM-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR2932813
head-neck@1
——0.847
220110025.TNBC
breast-umap@18
—E0.801
320130126.TNBC
breast-umap@18
—E0.797
4ERR2208919
melanoma-umap@29
——0.797
5SRR11296878
colon-landscapes@1
——0.787
6C3N-03662
lung-landscapes@6
—cohortSQ20.775
73e94d9d5-8c59-4366-babb-193bdc57d661
melanoma-umap@29
——0.770
8SRR12202460
bladder-landscape@3
——0.766
9TCGA-75-7027-01A-11R-1949-07
lung-landscapes@6
—cohortA40.764
1020020076.Her2HRpos
breast-umap@18
—C0.763

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
MYC_TARGETS_V20.500Idelalisib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
MYC_TARGETS_V10.400Inavolisib— uncovered
TGF_BETA_SIGNALING0.400Inavolisib— uncovered
GLYCOLYSIS0.300Inavolisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.300Idelalisib— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered
HEDGEHOG_SIGNALING0.200Inavolisib— uncovered
MTORC1_SIGNALING0.200Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.200Inavolisib— uncovered
ANDROGEN_RESPONSE0.100Inavolisib— uncovered
APICAL_JUNCTION0.100Inavolisib— uncovered
E2F_TARGETS0.100Inavolisib— uncovered
MITOTIC_SPINDLE0.100Inavolisib— uncovered
MYOGENESIS0.100Inavolisib— uncovered
NOTCH_SIGNALING0.100Inavolisib— uncovered
PROTEIN_SECRETION0.100Remibrutinib— uncovered